BOXED O
WARNING O
: O
WARNING O
: O
LACTIC O
ACIDOSIS O
WARNING O
: O
LACTIC O
ACIDOSIS O
Postmarketing O
cases O
of O
metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
have O
resulted O
in O
death B-NonOSE_AE
, O
hypothermia B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
and O
resistant O
bradyarrhythmias B-NonOSE_AE
. O

The O
onset O
of O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
is O
often O
subtle O
, O
accompanied O
only O
by O
nonspecific O
symptoms O
such O
as O
malaise B-NonOSE_AE
, O
myalgias B-NonOSE_AE
, O
respiratory B-NonOSE_AE
distress I-NonOSE_AE
, O
somnolence B-NonOSE_AE
, O
and O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
. O

Metformin-associated O
lactic B-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
was O
characterized O
by O
elevated B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
lactate I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
( O
> O
5 O
mmol/Liter O
) O
, O
anion B-OSE_Labeled_AE
gap I-OSE_Labeled_AE
acidosis I-OSE_Labeled_AE
( O
without O
evidence O
of O
ketonuria B-NonOSE_AE
or O
ketonemia B-NonOSE_AE
) O
, O
an O
increased B-OSE_Labeled_AE
lactate I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
pyruvate I-OSE_Labeled_AE
ratio I-OSE_Labeled_AE
, O
and O
metformin O
plasma O
levels O
generally O
> O
5 O
mcg/mL O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

Risk O
factors O
for O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
include O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
, O
concomitant O
use O
of O
certain O
drugs O
( O
e.g. O
, O
carbonic O
anhydrase O
inhibitors O
such O
as O
topiramate O
) O
, O
age O
65 O
years O
old O
or O
greater O
, O
having O
a O
radiological O
study O
with O
contrast O
, O
surgery O
and O
other O
procedures O
, O
hypoxic B-Not_AE_Candidate
states I-Not_AE_Candidate
( O
e.g. O
, O
acute B-Not_AE_Candidate
congestive I-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
) O
, O
excessive O
alcohol O
intake O
, O
and O
hepatic B-Not_AE_Candidate
impairment I-Not_AE_Candidate
. O

Steps O
to O
reduce O
the O
risk O
of O
and O
manage O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
in O
these O
high O
risk O
groups O
are O
provided O
in O
the O
full O
prescribing O
information O
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
, O
Contraindications O
( O
4 O
) O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Drug O
Interactions O
( O
7 O
) O
, O
and O
Use O
in O
Specific O
Populations O
( O
8.6 O
, O
8.7 O
) O
] O
. O

If O
metformin-associated O
lactic B-NonOSE_AE
acidosis I-NonOSE_AE
is O
suspected O
, O
immediately O
discontinue O
JANUMET O
and O
institute O
general O
supportive O
measures O
in O
a O
hospital O
setting O
. O

Prompt O
hemodialysis O
is O
recommended O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

EXCERPT O
: O
WARNING O
: O
LACTIC O
ACIDOSIS O
See O
full O
prescribing O
information O
for O
complete O
boxed O
warning O
. O

* O
Postmarketing O
cases O
of O
metformin-associated O
lactic O
acidosis O
have O
resulted O
in O
death O
, O
hypothermia O
, O
hypotension O
, O
and O
resistant O
bradyarrhythmias O
. O

Symptoms O
included O
malaise O
, O
myalgias O
, O
respiratory O
distress O
, O
somnolence O
, O
and O
abdominal O
pain O
. O

Laboratory O
abnormalities O
included O
elevated O
blood O
lactate O
levels O
, O
anion O
gap O
acidosis O
, O
increased O
lactate/pyruvate O
ratio O
, O
and O
metformin O
plasma O
levels O
generally O
> O
5 O
mcg/mL O
. O

( O
5.1 O
) O
* O
Risk O
factors O
include O
renal O
impairment O
, O
concomitant O
use O
of O
certain O
drugs O
, O
age O
> O
=65 O
years O
old O
, O
radiological O
studies O
with O
contrast O
, O
surgery O
and O
other O
procedures O
, O
hypoxic O
states O
, O
excessive O
alcohol O
intake O
, O
and O
hepatic O
impairment O
. O

Steps O
to O
reduce O
the O
risk O
of O
and O
manage O
metformin-associated O
lactic O
acidosis O
in O
these O
high O
risk O
groups O
are O
provided O
in O
the O
Full O
Prescribing O
Information O
. O

( O
5.1 O
) O
* O
If O
lactic O
acidosis O
is O
suspected O
, O
discontinue O
JANUMET O
and O
institute O
general O
supportive O
measures O
in O
a O
hospital O
setting O
. O

Prompt O
hemodialysis O
is O
recommended O
. O

( O
5.1 O
) O

